AstraZeneca Pharma IndiaNSE:ASTRAZEN -0.60%92 Dividend Yield % is 0.38% as of Jun. 26, 2026, which is 58% above its 10-year median of 0.24. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 92/100 and a GF Value™ of ₹10,868.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 516 Drug Manufacturers companies, AstraZeneca Pharma India ranks worse than 87.21% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of AstraZeneca Pharma India is 0.38%.
Good Sign:
AstraZeneca Pharma India Ltd stock Dividend Yield % is close to 1-year high.
The historical rank and industry rank for AstraZeneca Pharma India's Dividend Yield % or its related term are showing as below:
NSE:ASTRAZEN'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.02 Med: 0.24 Max: 0.63
Current: 0.38
During the past 13 years, the highest Dividend Yield of AstraZeneca Pharma India was 0.63%. The lowest was 0.02%. And the median was 0.24%.
NSE:ASTRAZEN's Dividend Yield % is ranked worse than 87.21% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs NSE:ASTRAZEN: 0.38
During the past 12 months, AstraZeneca Pharma India's average Dividends Per Share Growth Rate was 33.30% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 58.70% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 87.60% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of AstraZeneca Pharma India was 128.90% per year. The lowest was -38.40% per year. And the median was -9.10% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
AstraZeneca Pharma India (NSE:ASTRAZEN) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's Dividend Yield % falls into.
AstraZeneca Pharma India Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
AstraZeneca Pharma India Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 32.000000
2025-07-18
2025-07-18
2025-09-02
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Dividend Yield % of 0.38% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on AstraZeneca Pharma India and its competitors. This is 58% above median its historical median of 0.24. Over the past decade, AstraZeneca Pharma India's Dividend Yield % has ranged from 0.02 to 0.63. According to the industry distribution chart, AstraZeneca Pharma India ranks #450 out of 516 companies in the Drug Manufacturers industry, placing it in the top 87.2%.
Is AstraZeneca Pharma India's Dividend Yield % too high?
AstraZeneca Pharma India's current Dividend Yield % of 0.38% is 58% above median its 10-year median of 0.24. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.63. The Drug Manufacturers industry median Dividend Yield % is 2.03. AstraZeneca Pharma India's value of 0.38% is 81.3% below this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #450 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #450 out of 516 companies for Dividend Yield %. This places AstraZeneca Pharma India in the lower half of its industry. The industry median Dividend Yield % is 2.03. AstraZeneca Pharma India's value of 0.38% is 81.3% below this benchmark. Historically, AstraZeneca Pharma India's own Dividend Yield % has ranged from 0.02 to 0.63 over the past decade. While the company's 10-year median is 0.24 vs. the industry median of 2.03, AstraZeneca Pharma India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.03, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current Dividend Yield % of 0.38% is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Dividend Yield % is 0.38%, which is 58% above median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,868.58, compared to a current price of ₹8,391.00 — trading 22.8% below its estimated fair value. The current Dividend Yield % is 0.38%, which is 58% above median its 10-year median of 0.24 and 81.3% below the Drug Manufacturers industry median of 2.03. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Dividend Yield % is 0.38% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,391.00 is trading 22.8% below its estimated GF Value™ of ₹10,868.58.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
Dividend Yield %: 0.38% (58% above median its 10-year median of 0.24)
GF Value™: ₹10,868.58 vs. price of ₹8,391.00 (22.8% below fair value)
Industry Position: 81.3% below the Drug Manufacturers median (#450 of 516)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score
Get the complete analysis for NSE:ASTRAZEN
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
